Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Curr Opin Hematol. Author manuscript; available in PMC 2009 September 1.
Published in final edited form as:
PMCID: PMC2665692

The Platelet Release Reaction: Just when you thought platelet secretion was simple


Purpose of the Review

In response to agonists produced at vascular lesions, platelets release a host of components from their three granules: dense core, alpha, and lysosome. This releasate activates other platelets, promotes wound repair, and initiates inflammatory responses. While widely accepted, the specific mechanisms underlying platelet secretion are only now coming to light. This review focuses on the core machinery required for platelet secretion.

Recent Findings

Proteomic analyses have provided a catalogue of the components released from activated platelets. Experiments using a combination of in vitro secretion assays and knockout mice have lead to assignments of both v- and t-SNAREs (Soluble NSF Attachment Protein Receptors) to each of the three secretion events. SNARE knockout mice are also proving to be useful models for probing the role of platelet exocytosis in vivo. Other studies are beginning to identify SNARE regulators which control when and where SNAREs interact during platelet activation.


A complex set of protein-protein interactions control the membrane fusion events required for the platelet release reaction. SNARE proteins are the core elements but the proteins that control SNARE interactions represent key points at which platelet signaling cascades could affect secretion and thrombosis.

Keywords: SNAREs, exocytosis, VAMP-8/endobrevin, syntaxin


The most prominent structural features of a platelet are its three granules: dense core, alpha, and lysosomal. Activated platelets release material from these granules; but, what is the biological role of platelet secretion? The most obvious is a paracrine role since released ADP directly activates other platelets in the immediate area and serotonin affects smooth muscle cells. Released fibrinogen and von Willebrand Factor (vWF) play roles in thrombus stability. However, these clearly defined examples account for only a fraction of the proteins and small molecules released by platelets. There are a host of cytokines, chemokines, and growth factors released by platelets upon activation. While platelet exocytosis is understood in general terms, the molecular mechanisms involved have only recently been elucidated. With that understanding comes the tools to directly address the preconceived notions about platelet secretion and the ability to probe the specific roles of different exocytosis events.

Platelet Secretion

In humans, granule release deficiencies present as mild to moderate bleeding diatheses. While generally not life-threatening, the condition does pose risks e.g. during surgeries, childbirth, dental extractions. The two major class of Storage Pool Deficiencies (SPD), Hermansky-Pudlak Syndrome (HPS, δSPD) [15] and Gray Platelet Syndrome (GPS, αSPD) [6,7], are characterized by the loss of granule cargo from dense core granules for HPS and from α-granules for GPS. HPS patients show increased bleeding times, pigmentation defects (dense core granule biosynthesis is mechanistically similar to that of melanosomes), and lung fibrosis. There are 15 HPS-like mouse strains that have similar defects. Cloning of the defective genes and the subsequent analysis of their products has shown that the phenotypes are related to dysfunctional sorting of dense core granule proteins during biogenesis [3,4]. Most of the HPS genes encode proteins that participate in the sorting of cargo from and through endosomal compartments. GPS patients present with more heterogeneous bleeding defects but generally have normal pigmentation. Less is known about the underlying molecular defects that cause GPS, though one knockout mouse strain (transcription factor Hzf−/−) does display a loss of α-granule cargo [8]. In this strain, initial bleeding times are normal, yet the incidence of rebleeding is increased. One striking feature of GPS patients is that all have myelofibrosis [7]. This is perhaps due to the inability of the megakaryoctyes to retain synthesized growth factors. Consistently, plasma levels of Platelet Factor IV (PF4) and β-thromboglobulin (both are α-granule cargoes) are elevated in GPS patients. Little is known about the consequences of the inappropriate distribution of α-granule cargo. Patients with loss of both granules (αδSPD) are rare and do have bleeding defects [9,10]. These observations demonstrate the impact that release of platelet cargo has on hemostasis.

Platelet Granule Cargo

To date, more than 300 proteins and small molecules have been shown to be secreted from activated platelets [11]. This “secretome” can be classified by granular source and proposed function. Dense core granules mainly contain small molecules such as ADP, serotonin, and calcium. These components are critical for further platelet activation and vasoconstriction. As discussed above, failure to release these components does lead to defects in thrombosis. α-Granules contain protenacious components such as PF4, vWF, and platelet derived growth factor. These cargo proteins have the widest array of functions. Platelets also release lysosomal enzymes such as cathepsins and hexosaminidase which may play a role in clot remodeling or in further platelet activation. Functionally, the “secretome” can be divided into even more categories (reviewed in [12]). The most obvious class of proteins is the adhesive proteins such as fibrinogen, fibronectin, vitronectin, and thrombospondin which are released from α–granules and function in platelet-platelet binding and subsequent clot formation. Other membrane proteins, such as P-selectin, are sequestered in α-granules and exteriorized to the surface upon granule-plasma membrane fusion. Platelets also release fibrinolytic agents such as PAI-1 and TAFI which are important for clot remodeling. Perhaps the most diverse category is the mitogens such as IGF-1, VEGF, and bFGF. These proteins are thought to promote wound healing and angiogenesis through their stimulation of chemotaxis, cell proliferation, and maturation of the cells surrounding the wound site. Finally, platelets release a number of chemokines and cytokines such as RANTES, IL-8, and MIP1α which promote activation of passing leukocytes and lead to a range of immune responses. This releasate catalog suggests that platelet secretion is pivotal in establishing the microenvironment at the wound site. Therefore, controlling release from the granule stores, either specifically or globally, may prove to be an effective strategy to manipulate this microenvironment.

Granule Heterogeneity

It is becoming increasingly clear that our old monolithic view of platelet granules is overly simplistic. Recent studies have suggested that α-granules are heterogeneous in content and that that heterogeneity may result in differential release of granule cargo. Italiano and colleagues have shown that α-granules can be distinguished based on the pro or anti-angiogenic factors that they contain [13]. Anti-angiogenic factors, such as endostatin, reside in different granules than do pro-angiogenic factors such as VEGF. In human platelets, these two classes of granules can be differentially induced to release, depending on which PAR-directed agonist is used [13,14]. As similar degree of granule heterogeneity was initially reported by Storrie and colleagues who examined the localization of fibrinogen and vWF [15]. Functionally relevant granule heterogeneity is seen in other hematopoietic cells such as mast cells and neutrophils. In those systems, the differential release in response to distinct agonists appears mediated by different SNARE proteins [16,17]. As discussed below, differential use of t-SNAREs may account, in part, for the differential release of cargo from different classes of platelet granules; however, this remains to be addressed.

Secretory Machinery

Since the original description of SNAREs in neurons [18] much has been learned. Recent models of SNARE function posit that vesicle/granule-target membrane fusion is governed, in part, by the matching of a vesicle SNARE (v-SNARE), with a heterodimeric or trimeric, protein complex in the target membrane (t-SNAREs). This trans-membrane complex is the minimal element required for membrane fusion [19]. v-SNAREs are type II integral membrane proteins of generally low molecular weight (1525 kDa) which contain a characteristic 60–70 amino acid SNARE motif [20]. Human and mouse platelets contain VAMP-2/synaptobrevin, VAMP-3/cellubrevin, VAMP-7/TI-VAMP, and VAMP-8/endobrevin, with the later being the most abundant [2124]. t-SNAREs are of two types: the SNAP-23/25 type (SNAP-23, SNAP-25, SNAP-29, Sec9p), and the syntaxin type (syntaxin 1–19, etc.). The SNAP-23-like proteins have two SNARE motifs, lack transmembrane domains, but are generally anchored to the membrane through thioester-linked acyl groups. The type II membrane protein, syntaxins, contain the characteristic SNARE motif and an N-terminal regulatory domain [25]. Human platelets contain syntaxin 2, 4, 7, and 11 [2629] as well as SNAP-23 [30] and SNAP-29 [31]. The presence of SNAP-25 is perhaps controversial [31]. SNAREs employ the SNARE motifs to form a four-helix bundle arranged as a parallel coiled-coil [32]. This structure is stabilized by core hydrophobic interactions running the length of the bundle. Based on this inherent stability, the temporal and spatial control of SNARE complex formation and disassembly represent important tasks for the secretory machinery.

SNAREs in Platelets

Three groups have contributed to our present knowledge of the function of platelet SNAREs (for reviews see [33,34]). Our group [28] first showed that SNARE proteins are present in platelets and Flaumenhaft et al. [30] demonstrated a role for syntaxin 4 and SNAP-23 in α-granule release. Syntaxin 4 is also involved in lysosome release [27]. Subsequent work showed that SNAP-23 is involved in all three release events as is syntaxin 2 [26,27,35]. No role has been detected for syntaxin 7 and syntaxin 11’s role remains to be addressed. Based on these data, syntaxin 2 solely mediates dense core granule release but functionally overlaps with syntaxin 4 in mediating α-granule and lysosome release. This dual usage of syntaxin 2 and 4 might explain how differential release of subclasses of α-granules could occur. Perhaps syntaxin 2 promotes release of pro-angiogenic α-granules while syntaxin 4 mediates release of anti-angiogenic granules. This would imply that t-SNARE regulation may be the essential discriminator of which classes of cargo are released. Given the general usage of the v-SNARE, VAMP-8 (discussed below), this is an attractive model to explain the observations of Italiano et al. [13] and Ma et al. [14]; but, more direct analysis with knockout mice will be required to fully understand how the t-SNAREs could facilitate differential α-granule release.

Assigning roles for the v-SNAREs had been more ambiguous. Initial studies [30] showed that P-selectin exposure (α-granule release) was sensitive to Tetanus neurotoxin (a heterodimeric, zinc-dependent, endopeptidase specific for VAMP-1, -2, and -3 [36]). Subsequently, Feng et al. [37] showed that an anti-peptide antibody to the divergent N-terminus of VAMP-3 could inhibit α-granule release, suggesting a role for VAMP-3. However, these data were not consistent with the lack of a secretion defect in platelets from VAMP-3−/− mice [23]. Polgar et al. [22] showed that the cytoplasmic domains (containing the SNARE motif) of VAMP-3 and VAMP-8 could inhibit release from dense core and α-granules. Since the isolated cytoplasmic domains are promiscuous in their associations in vitro [38,39], it was uncertain whether the inhibitory effects were illustrative of a v-SNARE’s role or of the t-SNARE heterodimer’s binding preferences.

Recent work [24] has shown that VAMP-8/endobrevin is the primary v-SNARE in mouse platelets. VAMP-8−/− platelets have a clear secretion defect which is not seen in VAMP-3−/−, VAMP-2+/−, VAMP-2+/−/VAMP-3−/− platelets or from either permeabilized human or VAMP-3−/− platelets that have been treated with the catalytic Tetanus toxin light chain. The secretion defect in VAMP-8−/− platelets however was not complete. α-Granule and lysosome release were significantly affected even at high agonist doses and upon extended incubation; however, dense core granule release eventually approached wild-type levels. The VAMP-8-independent release could be eliminated by treatment with Tetanus toxin, suggesting that the secondary mechanism employed either VAMP-2 or -3. Preliminary experiments, using permeabilized human platelets and VAMP-8-specific Fab fragments, show that VAMP-8’s roles in mouse and human platelets are similar (Ren Q and Whiteheart SW, unpublished data).

The redundancy in v-SNARE usage is analogous to chromaffin cells [40], where there is a primary v-SNARE (VAMP-2) required for rapid and efficient, agonist-induced release, and a secondary v-SNARE (VAMP-3) which functions, albeit less efficiently, in the absence of the primary v-SNARE. Full ablation of release from chromaffin cells required deletion of both VAMP-2 and VAMP-3. The redundancy in VAMP usage observed in ex vivo platelet secretion assays is consistent with the in vivo thrombosis phenotype of the VAMP-8−/− mice. Upon laser injury, the VAMP-8−/− mice show a delay in thrombus formation and an increase in embolization, though the overall extent of platelet accumulation is not statistically different from wild-type (Graham et al. submitted).

In light of VAMP-8’s role in platelets, it is striking to note recent reports indicating that a Single Nucleotide Polymorphism (SNP) in the human VAMP-8 gene strongly correlates with early onset myocardial infarction (MI) [41,42]. The authors suggest that this SNP might affect VAMP-8 expression levels given its position in the gene’s 3’-untranslated region. One could hypothesize that heightened VAMP-8 levels would increase a platelet’s secretion ability, making it more likely to release its cargo and thus hyperthrombotic. However, further biochemical and functional analysis will be required to fully understand the ramifications of this genetic connection between VAMP-8 and early onset MI.

SNARE regulators

SNARE regulators control how and when SNARE proteins interact. Some are required to stabilize and sort SNAREs to appropriate membranes. Other regulators play key roles in promoting and selecting SNARE-SNARE interactions. Many of these regulators are sensitive to second messengers such as diacylglycerol and Ca2+ and others are substrates for kinases. While much is known about some of these SNARE regulators in other systems, relatively little is known about their precise roles in platelets. However, it has been possible to determine if the families are represented and in some cases whether they are important for platelet secretion. Syntaxin-binding proteins of the Munc18 family (a, b, and c [43]) are present in platelets. Antibodies that affect Munc18c binding to syntaxin 4 have a positive effect on release from permeabilized platelets [44], while peptides based on regulatory sequences of Munc18a and c are inhibitory [43]. Munc18 family members are phosphorylated in platelets and, though the significance of this is not yet clear, phosphorylation does affect Munc18 binding to syntaxins [43,44]. At least two members of the Munc13 family are present in platelets (Munc13-1 and Munc13-4; Schraw TD, Ren Q, and Whiteheart SW, unpublished data). In neurons, chromaffin cells, and cytotoxic T-cells, these proteins are important for granule docking/priming and SNARE engagement through interactions with the syntaxin t-SNAREs [4547]. Munc13-4 has been shown to be involved in dense core granule release via its interaction with the small GTP-binding proteins, Rab27a and b [48]. Other potential SNARE regulators such as DOC2α nd tomosyn are present in platelets (Ye S, Ren Q, Schraw, TD, and Whiteheheart SW, unpublished data) but their roles in secretion have not yet been probed.

Secretory Machinery as a Potential Therapeutic Target

The goal of anti-thrombotic therapies is a regimen that dampens thrombosis without inducing excessive bleeding. The secretory machinery might prove an effective target to accomplish this goal. In vivo analysis of the VAMP-8−/− mice shows a clear defect in laser-induced arteriole thrombosis but one not as complete as in an HPS mouse (Graham et al. submitted). Thrombi in VAMP-8−/− mice show a significant delay in initiation and well as a lack of stability. However, thrombi do form, and there is no significant difference in tail bleeding times in these animals. These data suggest that targeting the platelet’s primary, secretory machinery might be an effect way to manage thrombosis in vivo and thus limit clot formation without inducing excessive bleeding. Future analysis of other mouse strains with secretion deficient platelets is ongoing to validate this concept and to probe the additional roles that platelet exocytosis might play in the vasculature.


It is clear that activated platelets release material from their granular store. Recent work has catalogued that releasate and elucidated the core machinery that mediates the membrane fusion events required for release. With that knowledge the focus now turns to how the SNARE protein interactions are regulated during platelet activation. These studies have also produced the tools needed to address the importance of platelet secretion not only to thrombosis but also to the normal and pathogenic sequellae of vascular damage.


We would like to thank the members of the Whiteheart laboratory: Dr. Elena Matveeva, Dr. Zubair A. Karim, Wangsun Choi, Chunxia Zhao, and Rania Alhawas for their helpful discussions and careful reading of this manuscript. This work was supported by grants from the National Institutes of Health (HL56652 and HL091893) (to S.W.W.) and from the Ohio Valley Affiliate of the American Heart Association (0615238B) (to Q.R.).


Soluble NSF Attachment Protein Receptor
Vesicle Associate Membrane Protein
Storage Pool Deficiencies
Hermansky-Pudlak Syndrome
Gray Platelet Syndrome
Platelet Factor IV
von Willebrand Factor
Single Nucleotide Polymorphism
myocardial infarction

References and Suggested Reading

Papers of particular interest, published with the annual period of the review, have been highlighted as:

* Of special interest

** Of outstanding interest

1. Gunay-Aygun M, Huizing M, Gahl WA. Molecular defects that affect platelet dense granules. Semin Thromb Hemost. 2004;30:537–547. [PubMed]
2. Huizing M, Anikster Y, Gahl WA. Hermansky-Pudlak syndrome and related disorders of organelle formation. Traffic. 2000;1:823–835. [PubMed]
3. Li W, Rusiniak ME, Chintala S, et al. Murine Hermansky-Pudlak syndrome genes: regulators of lysosome-related organelles. Bioessays. 2004;26:616–628. [PubMed]
4. Swank RT, Novak EK, McGarry MP, et al. Mouse models of Hermansky-Pudlak syndrome: a review. Pigment Cell Res. 1998;11:60–80. [PubMed]
5. White JG. Platelet granule disorders. Crit Rev Oncol Hematol. 1986;4:337–377. [PubMed]
6. Smith MP, Cramer EM, Savidge GF. Megakaryocytes and platelets in alpha-granule disorders. Baillieres Clin Haematol. 1997;10:125–148. [PubMed]
7. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 2007;21:21–36. [PubMed]
8. Kimura Y, Hart A, Hirashima M, et al. Zinc finger protein, Hzf, is required for megakaryocyte development and hemostasis. J Exp Med. 2002;195:941–952. [PMC free article] [PubMed]
9. Hayward CP, Weiss HJ, Lages B, et al. The storage defects in grey platelet syndrome and alphadelta-storage pool deficiency affect alpha-granule factor V and multimerin storage without altering their proteolytic processing. Br J Haematol. 2001;113:871–877. [PubMed]
10. White JG, Keel S, Reyes M, Burris SM. Alpha-delta platelet storage pool deficiency in three generations. Platelets. 2007;18:1–10. [PubMed]
11. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103:2096–2104. [PubMed]
12. Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4–15. [PubMed]
13. Italiano JE, Jr, Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008;111:1227–1233. [PubMed] This manuscript presents data showing that a-granules are heterogeneous with respect to their pro and anti-angiogenic factors content.
14. Ma L, Perini R, McKnight W, et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A. 2005;102:216–220. [PubMed]
15. Sehgal S, Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost. 2007;5:2009–2016. [PubMed] This manuscript presents data showing that a-granules are heterogeneous with respect to their vWF and fibrinogen content.
16. Puri N, Roche PA. Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms. Proc Natl Acad Sci U S A. 2008;105:2580–2585. [PubMed] This manuscript presents data showing heterogeneity in agonist-stimulated release from mast cells.
17. Tiwari N, Wang CC, Brochetta C, et al. VAMP-8 segregates mast cell-preformed mediator exocytosis from cytokine trafficking pathways. Blood. 2008;111:3665–3674. [PubMed] This manuscript presents data showing heterogeneity in agonist-stimulated release from mast cells.
18. Söllner T, Whiteheart SW, Brunner M, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature. 1993;362:318–324. [PubMed]
19. Weber T, Zemelman BV, McNew JA, et al. SNAREpins: Minimal Machinery for Membrane Fusion. Cell. 1998;92:759–772. [PubMed]
20. Jahn R, Sudhof TC. Membrane fusion and exocytosis. Annu Rev Biochem. 1999;68:863–911. [PubMed]
21. Bernstein AM, Whiteheart SW. Identification of a cellubrevin/vesicle associated membrane protein 3 homologue in human platelets. Blood. 1999;93:571–579. [PubMed]
22. Polgar J, Chung SH, Reed GL. Vesicle-associated membrane protein 3 (VAMP-3) and VAMP-8 are present in human platelets and are required for granule secretion. Blood. 2002;100:1081–1083. [PubMed]
23. Schraw TD, Rutledge TW, Crawford GL, et al. Granule stores from cellubrevin/VAMP-3 null mouse platelets exhibit normal stimulus-induced release. Blood. 2003;102:1716–1722. [PubMed]
24. Ren Q, Barber HK, Crawford GL, et al. Endobrevin/VAMP-8 is the primary v-SNARE for the platelet release reaction. Mol Biol Cell. 2007;18:24–33. [PubMed] This manuscript presents data describing the v-SNARE requirements for platelet exocytosis.
25. Dietrich LE, Boeddinghaus C, LaGrassa TJ, Ungermann C. Control of eukaryotic membrane fusion by N-terminal domains of SNARE proteins. Biochim Biophys Acta. 2003;1641:111–119. [PubMed]
26. Chen D, Bernstein AM, Lemons PP, Whiteheart SW. Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 in dense core granule release. Blood. 2000;95:921–929. [PubMed]
27. Chen D, Lemons PP, Schraw T, Whiteheart SW. Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 and 4 in lysosome release. Blood. 2000;96:1782–1788. [PubMed]
28. Lemons PP, Chen D, Bernstein AM, et al. Regulated Secretion in Platelets: Identification of Elements of the Platelet Exocytosis Machinery. Blood. 1997;90:1490–1500. [PubMed]
29. McRedmond JP, Park SD, Reilly DF, et al. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics. 2004;3:133–144. [PubMed]
30. Flaumenhaft R, Croce K, Chen E, et al. Proteins of the exocytotic core complex mediate platelet alpha-granule secretion. Roles Of vesicle-associated membrane protein, snap-23, and syntaxin 4. J Biol. Chem. 1999;274:2492–2501. [PubMed]
31. Polgar J, Lane WS, Chung SH, et al. Phosphorylation of SNAP-23 in activated human platelets. J Biol Chem. 2003;278:44369–44376. [PubMed]
32. Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4Å resolution. Nature. 1998;395(6700):347–353. [PubMed]
33. Reed GL. Platelet secretory mechanisms. Semin Thromb Hemost. 2004;30:441–450. [PubMed]
34. Flaumenhaft R. Molecular basis of platelet granule secretion. Arterioscler Thromb Vasc Biol. 2003;23:1152–1160. [PubMed]
35. Lemons PP, Chen D, Whiteheart SW. Molecular mechanisms of platelet exocytosis: requirements for alpha- granule release. Biochem Biophys Res Commun. 2000;267:875–880. [PubMed]
36. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:717–766. [PubMed]
37. Feng D, Crane K, Rozenvayn N, et al. Subcellular distribution of 3 functional platelet SNARE proteins: human cellubrevin, SNAP-23, and syntaxin 2. Blood. 2002;99:4006–4014. [PubMed]
38. Fasshauer D, Antonin W, Margittai M, et al. Mixed and non-cognate SNARE complexes. Characterization of assembly and biophysical properties. J Biol Chem. 1999;274:15440–15446. [PubMed]
39. Yang B, Gonzalez L, Jr, Prekeris R, et al. SNARE interactions are not selective. Implications for membrane fusion specificity. J Biol Chem. 1999;274:5649–5653. [PubMed]
40. Borisovska M, Zhao Y, Tsytsyura Y, et al. v-SNAREs control exocytosis of vesicles from priming to fusion. EMBO J. 2005;24:5649–5653. [PubMed]
41. Shiffman D, O'Meara ES, Bare LA, et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2008;28:173–179. [PubMed] This manuscript presents a genetic study that correlates an SNP in VAMP-8 to early onset of mycardial infarctions.
42. Shiffman D, Rowland CM, Louie JZ, et al. Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26:1613–1618. [PubMed]
43. Schraw TD, Lemons PP, Dean WL, Whiteheart SW. A role for Sec1/Munc18 proteins in platelet exocytosis. Biochem J. 2003;374:207–217. [PubMed]
44. Houng A, Polgar J, Reed GL. Munc18-syntaxin complexes and exocytosis in human platelets. J Biol Chem. 2003;278:19627–19633. [PubMed]
45. Ashery U, Varoqueaux F, Voets T, et al. Munc13-1 acts as a priming factor for large dense-core vesicles in bovine chromaffin cells. EMBO J. 2000;19:3586–3596. [PubMed]
46. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3) Cell. 2003;115:461–473. [PubMed]
47. Rosenmund C, Sigler A, Augustin I, et al. Differential control of vesicle priming and short-term plasticity by Munc13 isoforms. Neuron. 2002;33:411–424. [PubMed]
48. Shirakawa R, Higashi T, Tabuchi A, et al. Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J Biol Chem. 2004;279:10730–10737. [PubMed]